Business
Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones
Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety
About this update from Erasca, Inc.
[{"type":"text","content":"Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for ERAS-0015 during dose escalation Initial Phase 1 monotherapy data for ERAS-0015 (potential best-in-class pan-RAS molecular glue) planned for H1 2026 and for ERAS-4001 (potential first-in-class pan-KRAS inhibitor) planned for H2 2026 SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced meaningful clinical progress for its RAS-targeting franchise and 2026-2027 milestones. “With both ERAS-0015 and ERAS-4001 INDs previously cleared in May 2025, Erasca’s strong operational execution continues to result in rapid clinical advancement of our RAS-targeting franchise. Notably, ERAS-0015 is now enrolling ahead of plan, thus providing early clinical data,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “During dose escalation, ERAS-0015 has already demonstrated promising early clinical activity with multiple ongoing confirmed and unconfirmed responses achieved, along with encouraging safety and tolerability data and well-behaved PK. We believe that observing first clinical responses in multiple patients at just 1/10th of the dose at which first clinical responses were observed with RMC-6236 is thesis-reinforcing in terms of ERAS-0015’s potential differentiation.” Pipeline Progress and 2026-2027 Milestones ERAS-0015 – Potential best-in-class RAS-targeting molecule Dose escalation in ongoing AURORAS-1 Phase 1 trial advancing faster than anticipated due to significant unmet medical need and high investigator and patient enthusiasmOngoing confirmed and unconfirmed responses observed in multiple patients with differing tumor types and RAS mutations Ongoing responses (two confirmed partial responses (PRs) and one unconfirmed PR) observed in patients with different tumor types and RAS mutations achieved at a low dose of 8 mg QDAdditional ongoing unconfirmed responses observed in patients at doses above 8 mg QD Favorable safety and tolerability, with no dose-limiting toxicities and predominantly low-grade adverse events observe...